Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPrEP Men's Study
NCT04898699Phase 1Completed
- Sponsor
- Columbia University
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emtricitabine and tenofovir in human immunodeficiency virus infection (HIV), sponsored by Columbia University. Primary endpoint: PrEP adherence at 6 months. Started Nov 2021; status: completed.
02
Drugs
emtricitabinetenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04898699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898699.